Track clinical trials in FiND Calendar to spot new opportunities in pharma sector
With a clear focus on reduction of the information arbitrage, Heckyl has built an alternative data platform FiND which collects and organizes macro, micro, and financial data to provide unique insights into pharmaceutical sector.
In our view, trading opportunities can be spotted in the stock market by discovery and analysis of vast amount of alternative data available on the web. One such data set is clinical trial study results for pharmaceutical companies.
Clinical trials are research studies that explore whether a drug or device is safe and effective for humans. The pharmaceutical products go through three phases of clinical trials followed by a regulatory approval process. After completing all three phases and the approval process, the company can start monetizing the drug or device.
The drugmakers report the progress of ongoing clinical trials for each phase from time to time. The result of late study trials (phase 2 and 3) can provide the best idea about a drug’s chances of approval. A favorable result of late study trials can be seen as positive by the market and vice-versa.
To help traders/ investors, we have introduced Calendar which tracks release dates for clinical trial, drug approval, patent expiry, operating stats and industry events.
We present a case study on Clearside Biomedical, Inc., a late-stage biopharmaceutical company developing drug therapies to treat back-of-the-eye diseases.
On Mar. 5, 2018, Clearside announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis (Image 1).
(Image 1: News screen for Clearside) Read the rest of this entry »